Krane Funds Advisors’s BeOne Medicines Ltd ONC Stock Holding History

Krane Funds Advisors’s Portfolio ONC Stock Details ONC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-21,861	Closed	-$2.95M	–	133
2022 Q3	$2.95M	Buy	21,861 +4	+0%	+$687	0.15%	34
2022 Q2	$3.54M	Sell	21,857 -1,095	-5%	-$171K	0.13%	33
2022 Q1	$4.33M	Buy	22,952 +1,974	+9%	+$420K	0.18%	43
2021 Q4	$5.68M	Sell	20,978 -4,107	-16%	-$1.39M	0.14%	46
2021 Q3	$9.11M	Sell	25,085 -2,641	-10%	-$863K	0.19%	39
2021 Q2	$9.52M	Sell	27,726 -121	-0.4%	-$40.1K	0.28%	38
2021 Q1	$9.69M	Buy	27,847 +7,134	+34%	+$2.36M	0.36%	29
2020 Q4	$5.35M	Buy	+20,713	New	+$5.7M	0.21%	29
2018 Q4	–	Sell	-232	Closed	-$40K	–	89
2018 Q3	$40K	Buy	+232	New	+$39K	﹤0.01%	75

Other funds holding ONC

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

CII

Capital International Inc Los Angeles, California $14.3B AUM 34.19% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Krane Funds Advisors's ONC Position: Q4 2022 in Review

Krane Funds Advisors sold out of BeOne Medicines Ltd (ONC) in Q4 2022, closing a stake of 21,861 shares — an estimated $2.95M sold.

Krane Funds Advisors first reported a position in ONC in Q3 2018 and held it in 9 quarters. The position peaked at $9.69M in Q1 2021. 212 funds tracked by Wall St. Rank hold ONC as of Q4 2022.

Krane Funds Advisors reported no remaining BeOne Medicines Ltd position as of Q4 2022 after selling out during the quarter.
Krane Funds Advisors sold 21,861 BeOne Medicines Ltd shares in Q4 2022, an estimated $2.95M.
Krane Funds Advisors first reported a position in BeOne Medicines Ltd in Q3 2018 and held it in 9 quarters.
Krane Funds Advisors's BeOne Medicines Ltd position peaked at $9.69M in Q1 2021.
212 funds tracked by Wall St. Rank held BeOne Medicines Ltd as of Q4 2022.

Based on Krane Funds Advisors's 13F filing for Q4 2022, filed 10 Feb 2023.